Thank you. My name is Peter Forsell, the CEO of Implantica. As you know, Implantica is all about bringing advanced technology into the body. For eventual new listeners, I will give a short little introduction of the company before we continue with the business update. Myself, I have invested rather lot of money into Implantica. Before the IPO, I invested around SEK 800 million in cash, and lately I offered to invest assets for SEK 1.2 billion, comprising 51% of my other private company. This will be decided on an EGM September 17, if that will be accepted or not. As you know, we have two platform technologies. One is a wireless energizing platform, so you really can keep going with advanced implants without running out of battery. We have an eHealth platform where we really could communicate and measure things inside the body, communicate with the caregiver. We can adapt and change the treatment on distance. We have been doing lots of work on this currently. We have been adapting this eHealth platform to our obesity product, the AppetiteControl. We have actually finalized the development, how we really should do this platform. This is currently under construction, and it's a very exciting work because this product will really change things when it really comes to the market. We are currently in the process to start animal testing in the U.S., so it's quite many new things on this product. We are controlling how much people are eating, so we have a food sensor that will be tested on these animals. We control the appetite by stretching, which also will be tested. Of course, we will then use the eHealth platform so we can communicate with the patient, healthcare provider, and so on. This, of course, especially of interest because we have 1.9 billion overweight people on this planet. If you can create a product that is very safe, don't even open the food passageway, don't damage anything, you can expect a rather exceptional market for this device. This is just for new listeners to show what fantastic patent portfolio we have. We actually have 300 individual inventions that have gone through market analysis, prototyping, and so on. We have selected 40 implant products that you have in the pipeline here. However, we are, of course, focusing on the main products here. The only product so far on the market is RefluxStop. I just wanted to explain shortly how this works for any new listener here. Actually, you have a muscle called the diaphragm that divides the chest from abdomen. In the chest, you are doing breathing. That means the diaphragm muscle is moving up and down, and pressure is coming and going in the chest. This pressure variation is then leaking out through this opening here when you have esophagus coming through, so the muscle could move freely. As soon as this sphincter here, the closing muscle between the stomach and esophagus, if this comes closer to the diaphragm, you start to be affected by these pressure variations. If you come close or even into the chest, you are lost. You for sure have acid reflux. If you can keep a large distance between the sphincter closing muscle and the diaphragm, then you don't have any reflux anymore. Our product, which is then placed on the outside of the stomach wall and invaginated in a little pouch, is then creating a mechanical stop. You always, independent of the movement of the diaphragm, you create this large distance to the closing sphincter muscle. That's then in total opposite to the existing treatments where you try to compress the food passageway and you create lots of problems for the patient with swallowing problems. They can't belch, they can't vomit, they get gas bloating because they don't get any gas up anymore and so on. Meanwhile, we have found the reason why you get acid reflux, the cause of acid reflux, and that's why our product is then so superior. You need to know that it's dangerous to have this disease. Actually, 48,000 people die in esophageal adenocarcinoma in Europe and U.S. alone. It's the last 40 years, a 10-fold expansion of this cancer. That's because the acid is coming up and terrorizing tissue over and over again. There's really a need for a new device here. Business update. First of all, we have filed our pre-submission for RefluxStop with the FDA in the U.S. We have also started a new subsidiary, Implantica Inc., to prepare for when FDA clearance occurs. We still don't know the answer from FDA. We know that we could have, if we are lucky, have a breakthrough designation program and be on the market in eight months. We know that if we are unlucky, we need to do a PMA it's called. That means we need to do another study of the same as LINX made, one year with 100 patients. This could then delay us several years, maybe even up to 2.5, three years if we are unlucky, if that is the case. However, in all circumstances, U.S. is a fantastic market, and we are doing the best to get to this market as soon as possible. Here you see a little bit what we have presented for the FDA because this is really interesting read for someone who is interested to invest in this company. Here you can see a comparison between the FDA trial of LINX, Johnson & Johnson's product, and our CE marking trial with RefluxStop. If you look at the left column here, you can see that we have a 24-hour pH monitoring, which means that you measure the pH in the esophagus for 24 hours. That's the standardized objective measurement to see does people have acid reflux or not. You can then say the answer is 42% of the LINX-operated people, they have still acid reflux. That's 10 x more than in our study. Still, you can see here that 68% of the patients have swallowing problems. We had 4%, and they both have it before surgery. This is like night and day. 25% have still heartburn, also pain. It's really huge difference. That's why we will conquer the world with this device. It's just all the admin processes, the regulatory approvals, the reimbursement processes that keeps the business down for the moment. RefluxStop commercialization is, of course, very interesting, and I will give you a little update. We are currently focusing on these markets you see here. In Germany, we have our own OPS code, our own reimbursement, our own DRG, and surgeons can just operate as much as they want. We don't have full payment yet, but it's still so we can have lots of hospitals starting up in Germany. In Austria, we also have some business, but that's mainly due to that they have more like a budget system. It's not strictly correlated only to a certain procedure, and therefore, we have some business. U.K. as well, we have a good in the public healthcare NHS system. We have a reasonable reimbursement as well. The other countries you see here a little bit lighter blue here. This is countries where we actually could sell. We have a good reimbursement situation, but it's a little bit more programmatic. In Italy, Spain, you need to negotiate with every hospital. It's a bit time-consuming, and you need to have the local knowledge about the culture and so on to be doing well here. Here you can see some summary of some of the hospitals that really has got going now after the pandemic. We have, for example, in Switzerland, we have Inselspital in Bern. That's the largest university hospital in Switzerland. They are regularly doing this kind of business now. We have a new member here, Hirslanden in Bern, Professor Steffen. Zehetner. Zehetner. Sorry. Zehetner. He has recently started with this, already done 17 cases. Very good surgeon. We also have Hirslanden in Zurich doing this. Also in Lucerne, they have just started. In Germany, we have, for example, Friedrichshafen. It's a huge reflux center. They do like 300 per year. Professor Lehmann there has really started doing lots of surgeries already in August, although it's holiday season. We have Steffen in Siegen, which is one of our demonstration centers here. We send surgeons to be trained. We have one of the most respected university hospitals in Germany called Charité in Berlin. It's a large university hospital. They have also started. We have in Austria, Professor Schoppmann. He is maybe the most well-known and respected reflux surgeon in Europe. It's the largest university hospitals in the whole of Europe. They do lots of reflux surgery, and they have already ordered 25 surgery pieces. We are coming in a situation now when it will be more and more hospitals added up. However, the pandemic still has caused problems with waiting lists, and the surgeon need to be trained. If they now want to start new centers, we need to train them first. It will be a little bit delay in terms of revenue, but you will see more and more centers coming up to convince you that this product going forward will be a very important product. We also are going on with the regulatory process, and also here, the pandemic, of course, has affected a bit the timelines. It's not as it was before, but we are continuously working on certain countries, and more and more countries will be approved going forward step by step. We have now got approval in New Zealand. We are also soon expecting in Austria. Sorry, Australia. I'm sleepy today. We will then attack these regions together when we now get the Australian approval as well. One significant event during the second quarter was we were able to raise an additional approximately SEK 600 million. This is through a directed new share issue. That means currently we're holding approximately EUR 147 million in cash in our account. The proceeds that we raise will be used to speed up the commercialization of RefluxStop and also to increase the functionality of the eHealth platform. Oh, wrong arrow. Yeah. In terms of research and development, we have been able to make a deal with a large company called Helbling here in Switzerland. They have 550 development engineers. Their main focus is medical implants. Here we have eight ongoing different R&D work streams. We are working, as I said before, on everything from data infrastructure, food sensor, ecosystem technology, and so on. It's very exciting times. We are working really hard to drive this project forward. Also, you have maybe read the press release. We pointed out here that I have offered Implantica to contribute 51% of my private health company, MedicalTree Swiss AG, valued by Ernst & Young to twice EUR 117 million, basically, or EUR 229 million, I think, euro. This is without any economic compensation as such. What I have asked the shareholders if I can do a split of my B shares. It works like this, that in Sweden, for example, you have shares with different voting rights. You have A and B shares. You can have 10 times voting power. In the U.S., they have another system where they can have much more voting power, the big American companies still could be the main shareholder, the main owners, so to say, from starting the company could still keep control over the American companies in a different way than you can in Sweden. In Switzerland, Liechtenstein, they have a system you could keep control, this is based on that one share has one vote. You can then divide the shares up, you reduce the value of the shares. If you have 100 shares with value SEK 100, you can do 200 shares with value SEK 50. You have no economical difference, but because one share is one vote, you can then increase the voting power. In this case, I already have much more than 2/3 voting power in this company to totally control the company. I am foreseeing that this company will become a large company. This will be a journey of transactions. It will be acquisitions. We will place all these different products on the market, and you can foresee that you will reduce the ownership over time. Although, of course, the value of the company will go up much more than the reduction in voting rights. For me then to be able to keep and continue this journey so we avoid a takeover from another company halfway, I have asked if that would be okay for the shareholders. I have been going around to the 10 largest shareholders and discussing most of them. Overall, people are positive to this, and I've sort of got the approval from the biggest shareholders that this is okay, and they see it as an advantage that I place all my inventions in the same basket, that I really believe in Implantica, and I have no intention to run any parallel stuff, and we should together build this large company we all hope that Implantica will become. We in MedicalTree Swiss AG, the new company then, we have four treatment areas and 15 products. Here you have the name of the products. Here you have the treatment field. We have implantable drug delivery, well, chemotherapy for cancer is one area which I will describe on the next slide a bit. We have a lubrication system for worn-out hips and knees. The problem with people when they wear out their hip, for example, is that all the cartilages disappear. In the cartilages, you produce oil for the motor. You produce some lubrication. When that disappears, you have the bad bone towards bad bone, and that doesn't work well. You can imagine the motor without oil. It just doesn't work. If you can then give that lubrication, you can avoid surgery, and you can have a normal hip instead of a replacement. We have lots of products that facilitate operation for laparoscopic surgery. Quite really interesting, really hot products you will hear about later. We have some treatments for heart failure, different kind of heart pumps and heart valves. Quite interesting, which will be disclosed step by step. We believe that these products fit very well together, with the eHealth platform that Implantica has developed. In this case, I will try to explain for you one of these 15 products, and that's actually for chemotherapy for cancer. Today, you actually have around 19.3 million cancer cases every year. The majority of these, they get chemotherapy or [Non-English content]. This is a market forecasted to 2027 reach $74 billion. It's a huge market we talk about here. The problem you have with this chemotherapy is that these drugs need to be given directly into the blood vessel. You give treatment for a very long time. You give a cure of maybe three weeks. You make some break. You take another three weeks. Break, another three weeks. It's very long-term, a big problem to give people all these drugs. The problem you have is you take a normal device to inject the infusion into your blood vessels. It's like a plastic tube, and you have a needle inside, and you put the needle through in one of your blood vessels in your arm or your hand. Then you take the needle out, and you leave the plastic tube. The problem you have is that blood is very aggressive to foreign material, and they get blood clots all the time. What happens then is that after two to three days, this doesn't work anymore because you just have blood clots around this plastic tube that you have in your blood vessel. Therefore, you try to do central vein catheters. You put a larger catheter into your larger blood vessel going close to the heart. We try to give drugs like this. However, after one month, two months, maybe, it doesn't work any longer then either, because the whole blood vessel just fill, the whole catheter is filled with blood clots. You have really serious problems for long-term treatment. There is not that many other drugs that also has the same problem. You need to give them for a long period of time. What we then have developed is a system where you can continue more or less endlessly to give drugs. This is a fully implantable system. You have a small little device that you place just under the skin. Here it looks like you have a really huge blood vessel here, but it's actually much smaller in real life. You have a little bit holder for the blood vessel here. You maybe free that 3 cm of blood vessel. You have a little membrane here, so the needle you have is inside, and it penetrates the self-closing, self-sealing membrane into the blood vessel, give the drug, and go back again. Because this needle could move, next time to the next place, the next place. If you have a 3 cm blood vessel, and you inject every millimeter, you can inject maybe 30x of this small 3 cm blood vessel. Then you can lift it and have another 30 x, then go down a bit and have another 30 x. You can inject maybe in 90 different position into your blood vessel, and that means that the blood vessel will heal. You can continue forever. It heals in between. Before you come from number one to number 90, it's already healed. This way, you can do really long-term treatment in a very effective way. This little doser here with the needle is then connected to a little bit larger system that you put in your abdominal wall, everything outside your abdomen. It's just under the fat, under the skin. There you can then refill with an injection port. You have a thick membrane, so you can stick through with a needle that has the hole on the side, not in the end. You can then fill one per week or one per month, depending on the drug. You can refill, everything could be automatically done. Today, these patients that get chemotherapy, they're either at the hospital, they could stay there for three weeks, or they come every day and get this dosage. Suddenly they can have the refill, and they could be at home, and the treatment could be controlled, and you can change treatment and so on, all on distance. This will save incredible lots of money for society. This is a very exciting future for the patients, I think, and we strongly believe in this, and this is an ongoing work, too. We will now start to integrate. If the investors approve this, we will start to integrate this system into the Implantica eHealth platform. We have been spending a significant amount of time over this period in recruitment. We've been reinforcing and enhancing the management team, and we're pleased to announce that we now have a new commercialization team set up at Implantica. We have recruited a new Chief Commercial Officer, Stefan Vogt. He just recently joined us. He comes with a vast amount of digital health experience. He was previously the Chief Commercial Officer at LifeWatch, which was a SIX Swiss Exchange listed company. Prior to that, a director of international business at Preventice Solutions, which was acquired by Boston Scientific. These were both cardio monitoring companies, digital companies, digital health companies. Steffen Schanz will be joining him. He's VP Marketing and Product Management. He also has significant experience in this area. He comes from Spinal Kinetics. Previously with Orthofix. Spinal Kinetics had purchased Orthofix. He held this position there. They had over 3,000 SKUs that he was responsible for. Prior to that, he also had a similar position at Karl Storz in various business segments there. Stephan Siegenthaler has been promoted to Chief Strategy Officer. He, as you might remember, developed the whole commercialization for the gastric band business together with Peter. He has very many contacts and knowledge of KOLs in this gastrointestinal area and surgical area. He will be developing the strategy together with Stefan Vogt and introducing them to the KOLs and involved in that process. We have two internal promotions. Gerhard Landwehr has been promoted to VP Business Development for DACH and U.K. He has a really rich experience in anti-reflux device sales. He was the general manager for Europe at EndoStim. EndoStim was a medical device that stimulated the lower esophageal sphincter to treat acid reflux. He also brought LINX, the LINX magnetic band, over to Europe, and he has very many contacts with really key opinion leaders. He's brought Sebastian Schoppmann to us, who's one of the most renowned anti-reflux surgeons in Europe. He will be developing the business in DACH and U.K. Henric Forsell has also joined this team. He has extensive company knowledge. He's been involved with the company for a very long product knowledge. He knows a lot of the KOLs, a lot of who he's met through the congresses, and he's going to be responsible for developing and executing the sales initiatives and market research together with Steffen Schanz. On the quality side, we have also a new hire, that's Juliette Cook. She's now our VP Quality and Regulatory. She is highly experienced, particularly also on the regulatory side, where she's obtained approvals and access to new markets in over 120 countries over her career. She is also an expert, let's say, in MDR, Medical Device Regulation, presents and trains regularly at congresses on the subject. That will really benefit us. She comes from Cochlear, where she was head of regulatory affairs there for EMEA. Previously, she was with Rayner Intraocular Lenses, where she was director of quality, clinical and regulatory affairs, and set up their whole quality department. We're very pleased to have these new members in our management team. Next slide is a little bit summary of what we already have talked about. Then we of course, come to the finances. I give the word over to our CFO, Andreas Öhrnberg. Many thanks, Peter. I will provide a brief review of the Q2 financials. Let us turn to slide number 28. Here we present top line, gross margin, and operating performance. Net revenues continued to grow over the Q2 period, from EUR 6,000 in Q2 2020 to EUR 115,000 in Q2 2021. That's despite restrictions on elective surgeries. Gross margin remained high on the back of very attractive product economics. Turning to operating performance, we saw the operating loss expanding from EUR 1.1 million in Q2 2020 to EUR 3 million in Q2 2021. This was driven by a material increase in OpEx, which is in line with our plan to accelerate the buildup of our commercial capabilities, and at the same time invest in R&D to move our pipeline products as well as the eHealth platform forward in parallel. Let us turn to slide 29. Here, looking at the balance sheet, we can see that our cash balance at the end of June amounted to EUR 147 million. The increase relates to the successful private placement of 4.9 million A shares in April, which generated EUR 59 million of gross proceeds. We have a solid balance sheet with no interest-bearing debt. Let us turn to slide 30. We outline the shareholdings per end of June. Here we can see that Implantica MedSwiss, the ultimate holding company, held 65% of the capital per end of June. Peter is the main shareholder in Implantica MedSwiss. Post an Implantica AG and Implantica MedSwiss merger, post that being approved, the indirect owners in Implantica MedSwiss would have direct ownership of Implantica AG SDRs. By having this holding structure being simplified would imply no dilution for existing shareholders. It would also imply Implantica AG free float increasing. With that, I would hand it back to Peter. I think it's time for any questions. Thank you. We have no questions, so I will pass back for any closing comments. Yeah. Thank you very much for listening, and most of you, I guess, also an investor of Implantica, and we should do our best to make you happy going forward. We really appreciate you taking the time to listen to us. Have a really good day. Thank you. Thank you.